Market Tracker

06/29 5:16pm ET

Impax Laboratories Inc (NASDAQ:IPXL)

29.13
Delayed Data
As of 4:00pm ET
 +0.29 / +1.01%
Today’s Change
27.62
Today|||52-Week Range
51.42
-31.88%
Year-to-Date
Teva Inches Closer to Completion of Allergan Generics Deal
Jun 28 / TheStreet.com - Paid Partner Content
Why Impax Laboratories, Werner Enterprises, and Planet Fitness Slumped Today
Jun 21 / MotleyFool.com - Paid Partner Content
Impax (IPXL) Stock Declines on Deal to Buy Generic Products
Jun 22 / Zacks.com - Paid Partner Content
Why Is Impax Labs Tumbling 11.7% Today
Jun 21 / MotleyFool.com - Paid Partner Content
Impax Laboratories (IPXL) Marked As A Dead Cat Bounce Stock
Jun 22 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close28.84
Today’s open29.64
Day’s range28.64 - 29.64
Volume528,659
Average volume (3 months)724,054
Market cap$2.1B
Dividend yield--
Data as of 4:00pm ET, 06/29/2016

Growth & Valuation

Earnings growth (last year)-33.33%
Earnings growth (this year)+21.89%
Earnings growth (next 5 years)+20.00%
Revenue growth (last year)+44.36%
P/E ratio60.4
Price/Sales3.58
Price/Book1.97

Competitors

 Today’s
change
Today’s
% change
MYGNMyriad Genetics Inc+0.99+3.35%
GLPGGalapagos NV+1.59+3.02%
GWPHGW Pharmaceuticals P...+1.28+1.39%
RAREUltragenyx Pharmaceu...-0.98-1.93%
Data as of 4:00pm ET, 06/29/2016

Financials

Next reporting dateAugust 2, 2016
EPS forecast (this quarter)$0.36
Annual revenue (last year)$860.5M
Annual profit (last year)$39.0M
Net profit margin4.53%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
President, Chief Executive Officer &
Director
George Frederick Wilkinson
Senior Vice President-
Global Operations
Andrew Schaschl
Corporate headquarters
Hayward, California

Forecasts